Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294541 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
A Phase 3 study, sponsored by Icagen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT00294541 is a Phase 3 study that was terminated before completion, run by Icagen. The registered enrollment target is 51 participants.
The verdict
NCT00294541, a Phase 3 study, was terminated before completion, sponsored by Icagen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
This trial is a follow-up companion study to Protocol ICA-17043-10, a Phase III, multi-center, efficacy and safety study of ICA-17043. This is an open-label extension study collecting safety data on the use of ICA-17043 in subjects with sickle cell disease (SCD) (e.g., HbSS, HbSC, HbSb0-thalassemia, HbSb+-thalassemia subjects). All subjects who have successfully completed ICA-17043-10 will, if deemed appropriate by their study Investigator and appropriate consent by subject is given, enroll in the ICA-17043-12 study (Study 12). Only patients who participated in ICA-17043-10 are eligible for this open label study
Interventions
- DRUG ICA-17043
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294541
The ClinicalTrials.gov registry entry for NCT00294541 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icagen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ICA-17043 is the first listed.
NCT00294541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294541 about?
NCT00294541 is a clinical study titled "A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy". This trial is a follow-up companion study to Protocol ICA-17043-10, a Phase III, multi-center, efficacy and safety study of ICA-17043. This is an open-label extension study collecting safety data on the use of ICA-17043 in subjects with sickle cell disease (SCD) (e.g., HbSS, HbSC, HbSb0-thalassemia,...
What is the current status of trial NCT00294541?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2006-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00294541?
The interventions under investigation include: ICA-17043 (DRUG).
Who is sponsoring clinical trial NCT00294541?
This trial is sponsored by Icagen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.